It is currently Mon Oct 20, 2014 2:16 pm

News News of Ampyra

Site map of Ampyra » Forum : Ampyra

Dalfampridine, or Ampyra, is a potassium channel blocker that is shown to improve visual function, motor skills and relieve fatigue in MS patients.


Hi friends is anybody living in SYDNEY and take ELAINE DELACK POKARIN. I wold be very greateful if someone can let me know how good this drug for m.s patients and the details where i can buy in SYDNEY.
seeva :roll:
Read more : RE:ELAINE DELACK POKARIN FOR M.S | Views : 1311 | Replies : 1

hi need help

Hi friends can anyone help me regarding LDN and AMPYRA. i am about to start the new medications compunded AMPYRA from next week.sametime i am taking LDN.. are there any one taking LDN while on the new medication AMPYRA.I would be very grateful any one let me know can i take LDN when i am taking ampyra,
seeva :roll:
Read more : hi need help | Views : 1582 | Replies : 8

Script process

My neuro suggested I try Ampyra and started the prescription process which is a real ordeal. I have to wait for a phone call, then call the compounding pharmacy, then call the other number back plus wait for insurance approval then they mail it to me. Is it worth taking or should I forget about it?
Read more : Script process | Views : 1396 | Replies : 0

monthly cost of Ampyra in Australia

is any body who live in Australia and take Fampyra? i need to know about the cost
Read more : monthly cost of Ampyra in Australia | Views : 2769 | Replies : 5

Fampyra, any other benefits

Hi all,

I was wondering if there are any other benefits associated with Fampyra other than improved walking speed. I am not particlarly concerned with my walking speed but with my walking. I really look like a wreck when I walk and can no longer walk unassisted. I also wonder about the side effects that caused a previous poster to cease after just one dose. Being able to walk better would be great but when ...
Read more : Fampyra, any other benefits | Views : 3144 | Replies : 3

Ampyra Sharing

I have no idea whether my post will be considered appropriate, but I am trying to be creative in finding a way to share a whole month's prescription of Ampyra from which I could tolerate only one pill. I understand why companies cannot take back medications, and while my neurologist's office in a large teaching hospital is sympathetic to all the medications that end up paid for, but not tolerated, there is nothing they can ...
Read more : Ampyra Sharing | Views : 1994 | Replies : 2

Conditional approval in EU for Fampyra


Biogen Idec Inc. said it received conditional approval from the European Commission for Fampyra to improve walking in adult patients with multiple sclerosis or MS who have walking disability. Fampyra is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS.

Fampyra can be used alone or in combination with disease modifying therapies, including immunomodulatory drugs.

"With its approval by the European Commission, Fampyra has ...
Read more : Conditional approval in EU for Fampyra | Views : 1839 | Replies : 0

Paediatric MS - Sam's Story, an update


Our darling Sam was diagnosed with MS at 5 years old, Sam is now 7, he will be 8 in October.

Sam has made his Dad and myself smile again, if you told us that 2 years ago I would never ever have believed it. But Sam has not had a clinical relapse since August 2009, we've had lots of scares and tears but I've learnt MS is so so wierd, you can havesymptoms ...
Read more : Paediatric MS - Sam's Story, an update | Views : 1611 | Replies : 1

Ampyra ® - improvement of patient-reported walking ability


Acorda Therapeutics, Inc. announced an analysis of pooled clinical trial results showed patients who were responders to Ampyra® (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

The data were presented at the 2011 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, ...
Read more : Ampyra ® - improvement of patient-reported walking ability | Views : 1931 | Replies : 1

EU agency recommends conditional approval of MS drug Fampyra


Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics Inc's (ACOR.O) drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis.

Acorda shares jumped 21 percent to $32.33 in premarket trading on Friday.

The European Medicines Agency, which advises the European Commission on whether to approve new drugs, said in a statement it has recommended giving the drug conditional approval.... Read More - ...
Read more : EU agency recommends conditional approval of MS drug Fampyra | Views : 1744 | Replies : 0


Login  •  Register


Total posts 220760 • Total topics 22871 • Total members 14444

Contact us | Terms of Service